Pexidartinib
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 193 publications
High Risk of Drug-Drug Interactions Caused by Pexidartinib via UDP-Glucuronosyltransferases Inhibition.
Journal: Chemical research in toxicology
Published: January 23, 2026
Management of tenosynovial giant cell tumor: approved and investigational therapies.
Journal: Expert review of anticancer therapy
Published: January 20, 2026
Targeting the DKK1/CSF1 Signaling Axis to Reprogram M2 Macrophages and Reverse Chemoresistance in Head and Neck Squamous Cell Carcinoma.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: September 27, 2025
Targeting CSF1R Attenuates the Development of Pulmonary Arterial Hypertension through CCL2.
Journal: American journal of respiratory cell and molecular biology
Published: September 23, 2025
PLX3397-Induced Microglial Ablation Alters Adipose Tissue Accumulation in a Male-Female-Dependent Manner Under High-Energy-Diet Feeding.
Journal: Nutrients
Published: September 12, 2025
Osteosarcoma-on-a-chip model mimicking intra-tumoral heterogeneity to interrogate tumor-associated macrophage reprogramming for immunotherapeutics.
Journal: Biomaterials
Published: August 22, 2025
Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.
Journal: Neuro-oncology advances
Published: August 04, 2025
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor.
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor.
Journal: Future oncology (London, England)
Published: July 05, 2025
Colony-stimulating factor-1 as a potential therapeutic target in asthenozoospermia.
Journal: Reproductive biology and endocrinology : RB&E
Published: July 04, 2025
Pexidartinib and Nintedanib Combination Therapy Targets Macrophage Polarization to Reverse Pulmonary Fibrosis: A Preclinical Study.
Journal: International journal of molecular sciences
Published: June 27, 2025
Diagnosis and Treatment Options in Pigmented Villonodular Synovitis of the Knee: A Narrative Review.
Diagnosis and Treatment Options in Pigmented Villonodular Synovitis of the Knee: A Narrative Review.
Journal: Journal of clinical medicine
Published: June 24, 2025
TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) program: 5-year retrospective hepatic safety assessment.
Journal: Future oncology (London, England)
Published: May 29, 2025
Last Updated: 02/24/2026